Transcribe and Document Claim Submission

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

Mar 28, 2026-- Takeda ( TSE:4502/NYSE:TAK ) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279 ...

Some results have been hidden because they may be inaccessible to you